Duloxetine in the management of diabetic peripheral neuropathic pain

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 343-356

  Ormseth, Michelle J ^a   Scholz, Beth A ^a   Boomershine, Chad S ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Diabetic peripheral neuropathic pain; Duloxetine; Review; Treatment

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; DULOXETINE; GABAPENTIN; PLACEBO; PREGABALIN; VENLAFAXINE;

ABNORMAL LABORATORY RESULT; ANOREXIA; ASTHENIA; ATRIOVENTRICULAR BLOCK; CARCINOMA; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCUSSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; IRRITABILITY; MELENA; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; NIGHTMARE; PARESTHESIA; PATIENT ATTITUDE; PATIENT MONITORING; PNEUMONIA; PROSTATE CANCER; QT INTERVAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; THORAX PAIN; TREATMENT OUTCOME; TREMOR; ULCER; VOMITING; WEAKNESS; WEIGHT CHANGE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84866500816     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S16358     Document Type: Review

References (75)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. Available at: https://apps.nccd.cdc.gov/DDTSTRS/FactSheet. aspx. Accessed May 20, 2011.
2. Centers for Disease Control and Prevention. Diabetes: disabling, deadly, and on the rise, 2005. Available at: http://www.cdc.gov/diabetes. Accessed May 20, 2011.
3. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetic Neuropathies: The Nerve Damage of Diabetes. NIH Publication No. 02-3185. May 2002. Available at: http://permanent.access. gpo.gov/lps19677/www.niddk.nih.gov/health/diabetes/pubs/neuro/ neuro.htm. Accessed May 20, 2011.
4. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
5. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research diagnostic purposes. Neurology. 2008;70:1630-1635.
6. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-1522.
7. Galer BS, Gianans A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
8. Jensen PG, Larson JR. Management of painful diabetic neuropathy. Drugs Aging. 2001;18:737-749.
9. Veves A, Manes C, Murray HJ, Young MJ, Boulton AJ. Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care. 1993;16:1187-1189.
10. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790-1795.
11. Wu N, Chen S, Boulanger L, et al. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Economics. 2009;12:192-202.
12. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus. A metaanalysis of controlled clinical trials. JAMA. 2001;286:1218-1227.
13. American Diabetes Association. Standards of Medical Care in Diabets-2010. Diabetes Care. 2010;33(Suppl 1):S11-S61.
14. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19:S2-S8.
15. Spiegel K, Leproult R, Van Cauter E. Impact of sleep dept on metabolic and endocrine function. Lancet. 1999;354:1435-1439.
16. Pfizer LYRICA DPN Physician ATU Study. February 26, 2007. Pfizer Inc, New York.
17. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143-149.
18. Sorensen L, Molyneaux L, Yue D. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycemic control. Diabetes Res Clin Pract. 2002;57:45-51.
19. Tesfaye S, Selvarajah D. The Eurodiab study: what has this taught us about diabetic peripheral neuropathy? Current Diabetes Reports. 2009;9:432-434.
20. Gemignani F. Acute painful diabetic neuropathy induced by strict glycemic control ("insulin neuritis"): the old enigma is still unsolved. Biomed Pharmacother. 2009;63:249-250.
21. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol. 2010;67: 534-541.
22. [No authors listed]. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1995;122:561-568.
23. Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia. 1994;37:579-584.
24. Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19:870-873.
25. Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982;5:386-390.
26. Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry. 1983;46:491-499.
27. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; May 2011.
28. Fields HL, Basbaum AI, Heinricher MM. Central nervous system mechanisms of pain modulation. In: McMahon SB, Koltzenberg M, editors. Wall and Melzack's Textbook of Pain. 5th ed. London, UK: Elsevier, Churchill, Livingston; 2006:125-142.
29. Lyrica [package insert]. New York: Pfizer Inc; 2011 May.
30. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clin Proc. 2006;81(Suppl 4):S12-S25.
31. Bril V, England J, Franklin GM, et al. Evidence-based Guideline: treatment of Painful Diabetic Neuropathy, Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Published concurrently in: Neurology. 2011;76:1758-65; Phys Med Rehab. 2011;3:345-352. e21; Muscle Nerve. 2011;43:910-917.
32. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001;3:53-62.
33. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine. 2005;6:346-356.
34. Goldstein DJ, Lu Y, Detke M, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.
35. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
36. Lunetta M, Le Moli R, Grasso G, Sangiorgio L. A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy. Diabetes Res Clin Practice. 1998;39:165-172.
37. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138.
38. Melzack R. The short-form McGill Pain Questionaire. Pain. 1987;30:191-197.
39. Ashkenazi A, Young WB. Dynamic mechanical (brush) allodynia in cluster headache. Headache. 2004;44:1010-1012.
40. Hamilton M. A rating scale for depression 1960. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
41. Guy W. ECDEI Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health; 1976:76-338.
42. Samuelsson M, Leffler A, Johansson B, Hansson P. On the repeatability of brush-evoked allydynia using a novel semi-quantitative method in patients with peripheral neuropathic pain. Pain. 2007;130:40-46.
43. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center 1993.
44. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
45. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996;67:588-597.
46. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897.
47. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-121.
48. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29-40.
49. Wernicke J, Raskin J, Rosen A, et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: an open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res Clin Exp. 2006;67:283-304.
50. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503-513.
51. Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009;25:623-631.
52. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7:373-385.
53. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;7: CD007115.
54. Garcia MJ, McNamara PM, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen-year follow-up study. Diabetes. 1974;23:105-111.
55. American Diabetes Association, the National Heart, Lung and Blood Institute; the Juvenile Diabetes Foundation international; the national Institute of Diabetes and Digestive and Kidney Disease, and the American heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132-1133.
56. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension. 2001;37:1053-1059.
57. Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28:301-306.
58. Moore WV, Fredrickson D, Brenner A, et al. Prevalence of hypertension in patient with type II diabetes in referral versus primary care clinics. J Diabetes Complications. 1998;12:302-306.
59. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacology. 2005;25:132-140.
60. Wernicke JF, Prakash A, Kajdasz DK, Houston J. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications. 2009;23:349-359.
61. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006;5:157-168.
62. Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30: 21-26.
63. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28:411-417.
64. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29-40.
65. Christensen JO, Swendsen OL. Bone mineral in pre-and postmenopausal women with insulin dependent and non-insulin dependent diabetes mellitus. Osteoporosis Int. 1999;10:307-311.
66. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
67. O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four f irst-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26:1045-1064.
68. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for US patients with diabetic peripheral neuropathic pain J Pain. 2006;7:399-407.
69. Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology. 2009;9:6.
70. Chen SY, Wu N, Boulanger L, et al. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy. Pain Pract. 2010;10:530-539.
71. Zhao Y, Wu N, Chen S, et al. Changes in opioid use and healthcare costs among US patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies. Curr Med Res Opin. 2010;26:2147-2156.
72. Solomon DH, Rassen JA, Glynn RF, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170: 1968-1976.
73. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67(Suppl 4):3-7.
74. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2005;89:207-212.
75. Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry. 2008;69: 95-105.